Liposomes for pulmonary drug delivery: The role of formulation and inhalation device design

Current Pharmaceutical Design

Volumn 23, Issue 3, 2017, Pages 362-372

  Elhissi, Abdelbary ^a  

^a Qatar University ^*  (Qatar)

Author keywords

Device; Inhalation; Liposome; Lung; Nanocarrier; Phosphatidylcholine; Proliposome

Indexed keywords

AMIKACIN; CIPROFLOXACIN; EXCIPIENT; LIPOSOME; PHOSPHOLIPID; DRUG CARRIER; NANOPARTICLE;

AIR JET NEBULIZER; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONTROLLED DRUG RELEASE; DEVELOPMENTAL STAGE; DEVICE SAFETY; DRUG FORMULATION; DRUG SAFETY; DRY POWDER INHALER; FREEZE DRYING; HUMAN; INHALER; LIPOSOMAL DELIVERY; LUNG; MEDICAL NEBULIZER; METERED DOSE INHALER; NEBULIZATION; PRIORITY JOURNAL; REVIEW; SOFT MIST INHALER; SPRAY DRYING; SPRAY FREEZE DRYING; ULTRASONIC NEBULIZER; ULTRASOUND; VIBRATING MESH NEBULIZER; ANIMAL; CHEMISTRY; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG DESIGN; NEBULIZER;

ANIMALS; CIPROFLOXACIN; CYSTIC FIBROSIS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPOSOMES; NANOPARTICLES; NEBULIZERS AND VAPORIZERS;

EID: 85015659279     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666161116114732     Document Type: Review

References (142)

1. Taylor G, Kellaway I. Pulmonary drug delivery. In: Hillery AM, Lloyd AW, Swarbrick J, Eds. Drug delivery and targeting for pharmacists and pharmaceutical scientists. London: Taylor and Francis 2001; pp. 269-300.
2. Stahlhofen W, Gebhart J, Heyder J. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J 1980; 41: 385-98.
3. O’Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997; 52(Suppl 2): S31-S44.
4. Carter KC, Puig-Sellart M. Nanocarriers made from non-ionic surfactants or natural polymers for pulmonary drug delivery. Curr Pharm Des 2016; 22: 3324-1.
5. Carvalho TC, McConville JT. The function and performance of aqueous aerosol devices for inhalation therapy. J Pharm Pharmacol 2016; 68: 556-78.
6. Khan I, Yousaf S, Alhnan MA, Ahmed W, Elhissi A, Jackson MJ. Design characteristics of inhaler devices used for pulmonary delivery of medical aerosols. In: Ahmed W, Jackson MJ, Eds. Surgical tools and medical devices. 2nd ed. Switzerland: Springer International Publishing 2016; pp. 573-579.
7. Taylor KMG, Taylor G, Kellaway IW, Stevens J. The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharm Res1989; 6: 633-6.
8. Saari M, Vidgren MT, Koskinen MO, Turjanmaa VMH, Nieminen MM. Pulmonary distribution and clearance of two beclomethasone formulations in healthy volunteers. Int J Pharm 1999; 181: 1-9.
9. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238-52.
10. Kirby CJ, Gregoriadis G. Liposomes. In: Mathiowitz E, Ed. Encyclopaedia of controlled drug delivery. NewYork: John Wiley 1999; pp. 461-92.
11. Payne NI, Timmins P, Ambrose CV, Ward MD, Ridgway F. Proliposomes: A novel solution to an old problem. J Pharm Sci 1986; 75: 325-9.
12. Elhissi AMA, Taylor KMG. Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers. J Drug Deliv Sci Tech 2005; 15: 261-5.
13. Olson F, Hunt LA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1979; 557: 9-23.
14. Hope MJ, Bally MB, Mayer LD, Janoff AS, Cullis PR. Generation of multilamellar phospholipid vesicles. Chem Phys Lipids 1986; 40: 89-107.
15. Hinna A, Steiniger F, Hupfeld S, Stein P, Kuntsche J, Brandl M. Filter-extruded liposomes revisited: a study into size distributions and morphologies in relation to lipid-composition and process parameters. J Liposome Res 2015; 26: 11-20.
16. Elhissi AM, Islam A, Arafat BT, Taylor M, Ahmed W. Development and characterisation of freeze-dried liposomes containing two anti-asthma drugs. Micro Nano Lett 2010; 5: 184-8.
17. Gala R, Khan I, Elhissi AM, Alhnan MA. A comprehensive production me; thod of self-cryoprotected nano-liposome powders. Int J Pharm 2015; 486: 153-8.
18. Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013; 68: 818-25.
19. Waldrep JC, Scherer PW, Hess GD, Black M, Knight V. Nebulized glucocortecoids in liposomes: Aerosol characteristics and human dose estimates. J Aerosol Med 1994; 7: 135-45.
20. Letsou GV, Safi HJ, Reardon MJ, et al. Pharmacokinetics of liposomal aerosolized cyclosporin A for pulmonary immunosupression. Ann Thorac Surg 1999; 68: 2044-8.
21. Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20 (s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004; 10: 2319-26.
22. Ehsan Z, Wetzel JD, Clancy JP. Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients. Expert Opin Investig Drugs 2014; 23: 743-9.
23. Ehsan Z, Clancy JP. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Microbiol 2015; 10: 1901-12.
24. Latimer P, Menchaca M, Snyder RM, et al. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp Biol Med (Maywood) 2009; 234: 1244-52.
25. Nasr M, Taha I, Hathout RM, Suitability of liposomal carriers for systemic delivery of risedronate using the pulmonary route. Drug Deliv 2013; 20: 311-8.
26. Morimoto Y, Adachi Y, Pulmonary uptake of liposomal phosphatidylcholine upon intratracheal administration to rats. Chem Pharm Bull 1982; 30: 2248-51.
27. Barker SA, Taylor KMG, Short MD. The deposition and clearance of liposome entrapped 99mTc-DTPA in the human respiratory tract. Int J Pharm 1994; 102: 159-65.
28. Albasarah YY, Somavarapu S, Stapleton P, Taylor KM. Chitosan-coated antifungal formulations for nebulisation. J Pharm Pharmacol 2010; 62: 821-8.
29. Kamalaporn H, Leung K, Nagel M, et al. Aerosolized liposomal Amphotericin B: a potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients. Pediatr Pulmonol 2014; 49: 574-80.
30. Conley J, Yang H, Wilson T, et al. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother 1997; 41: 1288-92.
31. Cipolla D, Blanchard J, Gonda I, Development of liposomal ciprofloxacin to treat lung infections. Pharmaceutics 2016; 8:, pii: E6. doi: 10.3390/pharmaceutics8010006.
32. Gilbert BE, Wilson SZ, Garcon NM, Wyde PR, Knight V. Characterization and administration of cyclosporine liposomes as a small-particle aerosol. Transplantation 1993; 56: 974-7.
33. Behr J, Zimmermann G, Baumgartner R, et al. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J Aerosol Med Pulm Drug Deliv 2009; 22: 121-30.
34. Stern M, Sorgi F, Hughes C, et al. The effects of jet nebulisation on cationic liposome-mediated gene transfer in vitro. Gene Ther 1998; 5: 583-93.
35. Guillaume C, Delépine P, Droal C, Montier T, Tymen G, Claude F. Aerosolization of cationic lipid-DNA complexes: Lipoplex characterization and optimization of aerosol delivery conditions. Biochem Biophys Res Commun 2001; 286: 464-71.
36. Davies LA, Nunez-Alonso GA, McLachlan G, Hyde SC, Gill DR. Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy. Hum Gene Ther Clin Dev 2014; 25: 97-107.
37. Mitra R, Pezron I, Li Y, Mitra AK. Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids. Int J Pharm 2001; 217: 25-31.
38. Kanaoka E, Nagata S, Hirano K. Stabilization of aerosolized IFN-γ by liposomes. Int J Pharm 1999; 188: 165-72.
39. Birchall JC, Kellaway IW, Gumbleton M. Physical stability and invitro gene expression efficiency of nebulised lipid-peptide-DNA complexes. Int J Pharm 2000; 197: 221-31.
40. Manunta MD, McAnulty RJ, Tagalakis AD, et al. Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium. PLoS One 2011; 6: e26768.
41. Elhissi A, Ahmed W. Chapter 1: Advances in design and technology of devices manufactured for drug delivery applications. In: Jackson MJ, Davim JP, Eds. Medical device manufacturing. USA: Nova Publishers 2011.
42. King RJ. Isolation and chemical composition of pulmonary surfactant. In: Robertson B, Van Gold LMG, Batenburg JJ, Eds. Pulmonary surfactant. Amsterdam: Elsevier 1984; pp. 1-15.
43. Finley TN, Pratt SA, Ladman AJ, Brewer L, McKay MB. Morphological and lipid analysis of the alveolar lining material in dog lung. J Lipid Res 1968; 9: 357-65.
44. Ivey H, Roth S, Kattwinkel J. Nebulization of sonicated phospholipid for treatment of respiratory distress syndrome of infancy. Paediater Res 1977; 11: 573.
45. Morimoto Y, Adachi Y. Pulmonary uptake of liposomal phosphatidylcholine upon intratracheal administration to rats. Chem Pharm Bull 1982; 30: 2248-51.
46. Schreier H, McNicol KJ, Ausborn M, et al. Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep. Int J Pharm 1992; 87: 183-93.
47. Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997; 79: 1409-21.
48. Jendle J, Karlberg BE, Persliden J, Franzen L, Arborelius M. Jr, Delivery and retention of an insulin aerosol produced by a new jet nebulizer. J Aerosol Med 1995; 8: 243-54.
49. Gilbert BE, Knight C, Alvarez FG, et al. Tolerance of volunteers to cyclosporin A-dilauroylphosphatidylcholine liposome aerosol. Am J Respir Crit Care Med 1997; 156: 1789-93.
50. Waldrep JC, Gilbert BE, Knight CM, et al. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance Safety Chest 1997; 111: 316-23.
51. Girod DBS, Bajolet-Laudinat O, Dupuit F, et al. Protection of human respiratory epithelium from pseudomonas aeruginosa adherence by phosphatidylglycerol liposomes. Infect Immun 1994; 62: 704-8.
52. Farr S J, Kellaway IW, Carman-Meakin B. Assessing the potential of aerosol-generated liposomes from pressurised pack formulations. J Control Release 1987; 5: 119-27.
53. Vyas SP, Sakthivel, Pressurized pack-based liposomes for pulmonary targeting of isoprenaline-development and characterization. J Microencapsul 1994; 11: 373-80.
54. Tiwari D, Goldman D, Malick WA, Madan PL. Formulation and evaluation of albuterol metered dose inhalers containing tetra-fluoroethane (P134a), a non-CFC propellant. Pharm Dev Technol 1998; 3: 163-74.
55. Tarara TE, Hartman MS, Gill H, Kennedy AA, Weers JG. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharm Res 2004; 21: 1607-14.
56. Hirst PH, Pitcairn GR, Weers JG, et al. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm Res 2002; 19: 258-64.
57. Weers J, Tarara T. The PulmoSphere™ platform for pulmonary drug delivery. Ther Deliv 2014; 5: 277-95.
58. Radhakrishnan R, Mihalko PJ, Abra RM. Method and apparatus for administering dehydrated liposomes by inhalation. US patent No. 4895719 1990.
59. Seville PC, Kellaway IW, Birchall JC. Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. Gene Med 2002; 4: 428-37.
60. Lo YL, Tsai JC, Kuo JH. Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase. J Control Release 2004; 94: 259-72.
61. Chougule MB, Padhi BK, Misra A. Nano-liposomal dry powder inhaler of Amiloride Hydrochloride. J Nanosci Nanotechnol 2006; 6: 3001-9.
62. Chougule M, Padhi B, Misra A. Development of spray dried liposomal dry powder inhaler of Dapsone. AAPS PharmSciTech 2008; 9: 47-53.
63. Manca ML, Valenti D, Sales OD, Nacher A, Fadda AM, Manconi M. Fabrication of polyelectrolyte multilayered vesicles as inhalable dry powder for lung administration of rifampicin. Int J Pharm 2014; 472: 102-9.
64. Ourique AF, Chaves Pdos S, Souto GD, Pohlmann AR, Guterres SS, Beck RC. Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: development, in vitro characterization and antioxidant activity. Eur J Pharm Sci 2014; 65: 174-82.
65. Alves GP, Santana MHA. Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties. Powder Technol 2004; 145: 139-48.
66. Rojanarat W, Changsan N, Tawithong E, Pinsuwan S, Chan HK, Srichana T. Isoniazid proliposome powders for inhalation preparation, characterization and cell culture studies. Int J Mol Sci 2011; 12: 4414-34.
67. Schreier H, Mobley WC, Concessio N, Hickey AJ, Niven RW. Formulation and in vitro performance of liposome powder aerosol. STP Pharm Sci 1994; 4: 38-44.
68. Holzner P, Sorgi F, Schreier H, Hickey AJ. Preparation of dry powder liposome aerosols for gene delivery to the lung by jet-milling. Respir Drug Deliv 1998; VI: pp. 349-50.
69. Mobley WC. The effect of jet-milling on lyophilized liposomes. Pharm Res 1998; 15: 149-52.
70. Joshi M, Misra A. Dry powder inhalation of liposomal ketotifen fumarate: formulation and characterization. Int J Pharm 2001; 223: 15-27.
71. Joshi MR, Misra A. Liposomal budesonide for dry powder inhaler: preparation and stabilization. AAPS PharmSciTech 2001; 2: article 25.
72. Joshi M, Misra A. Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. Clin Exp Pharmacol Physiol 2003; 30: 153-6.
73. Shah SP, Misra A. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech 2004; 5: e65.
74. Shah SP, Misra A. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance. Pharmazie 2004; 59: 812-3.
75. Lu D, Hickey AJ. Liposomal dry powders for pulmonary delivery of proteins. AAPS PharmSciTech 2005; 6: E641-8.
76. Changsan N, Chan HK, Separovic F, Srichana T. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci 2009; 98: 628-39.
77. Parmar JJ, Singh DJ, Lohade AA, et al. Inhalational system for Etoposide liposomes: formulation development and in vitro deposition. Indian J Pharm Sci 2011; 73: 656-62.
78. Desai TR, Wong JP, Hancock RE, Finlay WH. A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleteriouseffects of milling. J Pharm Sci 2002; 91: 482-91.
79. Sweeney LG, Wang Z, Loebenberg R, Wong JP, Lange CF, Finlay WH. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005; 305: 180-5.
80. Bi R, Shao W, Wang Q, Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target 2008; 16: 639-48.
81. Desai TR, Hancock REW, Finlay WH. Delivery of liposomes in dry powder form: aerodynamic dispersion properties. Eur J Pharm Sci 2003; 20: 459-67.
82. Deshpande D, Blanchard J, Srinivasan S, et al. Aerosolization of lipoplexes using AERx® pulmonary delivery system. AAPS PharmSci 2002; 4: 1-10.
83. Mudumba S, Deshpande D, Sanders R, et al. Non-viral delivery of COX-1 gene by the AERx® pulmonary delivery syatem. Respir Drug Deliv 2004; 2: 353-6.
84. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002; 47: 1406-16.
85. McCallion ONM, Taylor KMG, Thomas M, Taylor AJ. Nebulisation of monodisperse latex sphere suspensions in air-jet and ultrasonic nebulisers. Int J Pharm 1996; 133: 203-14.
86. Najlah M, Parveen I, Alhnan MA, et al. The effects of suspension particle size on the performance of air-jet, ultrasonic and vibrating-mesh nebulisers. Int J Pharm 2014; 461: 234-41.
87. Gilbert BE, Six HR, Wilson SZ, Wyde PR, Knight V. Small-particle aerosol of enviroxime-containing liposomes. Antiviral Res 1988; 9: 355-6.
88. Taylor KMG, Taylor G, Kellaway IW, Stevens J. The stability of liposomes to nebulisation. Int J Pharm 1990; 58: 57-61.
89. Bridges PA, Taylor KMG. Nebulisers for the generation of liposomal aerosols. Int J Pharm 1998; 173: 117-25.
90. Elhissi AM, Faizi M, Naji WF, Gill HS, Taylor KM. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharm 2007; 334: 62-70.
91. Leung KKM, Bridges PA, Taylor KMG. The stability of liposomes to ultrasonic nebulisation. Int J Pharm 1996; 145: 95-102.
92. McCallion ON, Taylor KM, Thomas M. Taylor AJ. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res 1995; 12: 1682-8.
93. Niven RW, Schreier H. Nebulization of liposomes. I. Effects of lipid composition. Pharm Res 1990; 7: 1127-32.
94. Niven RW, Carvajal TM, Schreier H. Nebulization of liposomes. III. The effects of operating conditions and local environment. Pharm Res 1992; 9: 515-20.
95. Niven RW, Speer M, Schreier H. Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm Res 1991; 8: 217-21.
96. Elhissi AMA, Karnam KK, Danesh-Azari M-R, Gill HS, Taylor KMG. Formulations generated from ethanol-based proliposomes for delivery via medical nebulisers. J Pharm Pharmacol 2006; 58: 887-94.
97. Bridges PA, Taylor KMG. The effects of freeze-drying on the stability of liposomes to jet nebulization. J Pharm Pharmacol 2000; 53: 393-8.
98. Niven RW, Ip AY, Mittelman SD, Farrar C, Arakawa T, Prestrelski SJ. Protein nebulization: I. Stability of lactate dehydrogenase and recombinant granulocyte colony stimulating factor to air-jet nebulization. Int J Pharm 1994; 109: 17-26.
99. Niven RW, Prestrelski SJ, Treuheit MJ, Ip AY, Arakawa T. Protein nebulization II. Stabilization of G-CSF to air-jet nebulization and the role of protectants. Int J Pharm 1996; 127: 191-201.
100. Fängmark I, Carpin JC. Stability of urease during aerosolization: the effect of operating conditions. J Aerosol Sci 1998; 29: 279-88.
101. Kanaoka E, Nagata S, Hirano K. Stabilization of aerosolized IFN-γ by liposomes. Int J Pharm 1999; 188: 165-72.
102. Khatri L, Taylor KMG, Craig DQM, Palin K. An assessment of jet and ultrasonic nebulisers for the delivery of lactate dehydrogenase solutions. Int J Pharm 2001; 227: 121-31.
103. Khatri L, Taylor, KMG, Craig DQM, Palin K. The stability of liposome entrapped lactate dehydrogenase to nebulisation. J Pharm Pharmacol 2004; 56: S-41.
104. Hajos F, Stark B, Hensler S, Prassl R, Mosgoeller W. Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm 2008; 357: 286-94.
105. Crook K, McLachlan G, Stevenson BJ, Porteous DJ. Plasmid DNA molecules complexed with cationic liposomes are protected from degradation by nucleases and shearing by aerosolisation. Gene Ther 1996; 3: 834-9.
106. Eastman SJ, Tousignant JD, Lukason MJ, et al. Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid:DNA complexes. Hum Gene Ther 1997; 8: 313-22.
107. Schwarz LA, Johnson JL, Black M, Cheng SH, Hogan ME, Waldrep JC. Delivery of DNA-cationic liposome complexes by small-particle aerosol. Hum Gene Ther 1996; 7: 731-41.
108. Stern M, Sorgi F, Hughes C, et al. The effects of jet nebulisation on cationic liposome-mediated gene transfer in vitro. Gene Ther 1998; 5: 583-93.
109. Densmore CL, Giddings TH, Waldrep JC, Kinsey BM, Knight V. Gene transfer by guanidinium-cholesterol: dioleoylphosphatidyl-ethanolamine liposome-DNA complexes in aerosol. J Gene Med 1999; 1: 251-64.
110. Birchall JC, Kellaway IW, Gumbleton M. Physical stability and invitro gene expression efficiency of nebulised lipid-peptide-DNA complexes. Int J Pharm 2000; 197: 221-31.
111. Finlay WH, Wong JP. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int J Pharm 1998; 167: 121-7.
112. Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006; 113: 9-14.
113. Guillaume C, Delépinea P, Droalb C, Montiera T, Tymenb G, Claude F. Aerosolization of Cationic Lipid–DNA Complexes: Lipoplex characterization and optimization of aerosol delivery conditions. Biochem Biophys Res Comm 2001; 286: 464-71.
114. Bitterle E, Keller M, Akkar A, Steinfuehrer K, Menges G. Nebulization of liposomal ciclosporin A formulation by eFlow 30L: Correlation between in-vitro and in-vivo results. Poster No 260, 20th Annual North American Cystic Fibrosis Conference, Denver, Colorado USA 2006.
115. Keller M, Menges G, Behr J, Baumgartner G, Sommerer K, Seitz J. Lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a liposomal ciclosporin A (CsA) formulation by the eFlow electronic nebuliser. 3oth European Cystic Fibrosis Conference, Belek, Turkey 2007.
116. Kleemann E, Schmehl T, Gessler T, Bakowsky U, Kissel T, Seeger W. Iloprost-containing liposomes for aerosol application in pulmo- nary arterial hypertension: formulation aspects and stability. Pharm Res 2007; 24: 277-87.
117. Gaspar MM, Gobbo O, Ehrhardt C. Generation of liposome aerosols with the Aeroneb Pro and the AeroProbe nebulizers. J Liposome Res 2010; 20: 55-61.
118. Ghazanfari T, Elhissi AM, Ding Z, Taylor KM. The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int J Pharm 2007; 339: 103-11.
119. Zhang G, David A, Wiedmann TS. Performance of the vibrating membrane aerosol generation device: Aeroneb Micropump Nebulizer. J Aerosol Med 2007; 20: 408-16.
120. Najlah M, Vali A, Taylor M, et al. A study of the effects of sodium halides on the performance of air-jet and vibrating-mesh nebulizers. Int J Pharm 2013; 456: 520-7.
121. Lange CF, Hancock REW, Samuel J, Finlay WH. In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J Pharm Sci 2001; 90: 1647-57.
122. Desai TR, Wong JP, Hancock REW, Finlay WH. A facile method of delivery of liposomes by nebulization. J Control Release 2002; 84: 69-78.
123. Elhissi A, O’Neill M, Ahmed W, Taylor KM. High-sensitivity differential scanning calorimetry for measurement of steroid entrapment in nebulised liposomes generated from proliposomes. Micro Nano Lett 2011; 6: 694-7.
124. Vidgren M, Waldrep JC, Arppe J, et al. A study of 99mtechnetiumlabelled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosols in normal volunteers. Int J Pharm 1995; 115: 209-16.
125. Waldrep JC, Scherer PW, Keyhani K, Knight V. Cyclosporin A liposome aerosol: Particle size and calculated respiratory deposition. Int J Pharm 1993; 97: 205-12.
126. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. Liposomes for drug delivery to the lungs by nebulisation. Eur J Pharm Biopharm 2007; 67: 655-66.
127. Subramanian S, Khan I, Korale O, et al. A simple approach to predict the stability of phospholipid vesicles to nebulization without performing aerosolization studies. Int J Pharm 2016; 502: 18-27.
128. Bridges PA, Taylor KMG. An investigation of some of the factors influencing the jet nebulisation of liposomes. Int J Pharm 2000; 204: 69-79.
129. Waldrep JC, Arppe J, Jansa KA, Knight V. High dose cyclosporin A and budesonide-liposome aerosols. Int J Pharm 1997; 152: 27-36.
130. Bridges PA, Taylor KMG, McCallion ONM. Nebulisation of liposomes- the effects of formulation variables. In: Drug Delivery to the Lungs VI. Bristol: The Aerosol Society 1995; pp. 81-4.
131. Marks LB, Oberdörster G, Notter RH. Generation and characterization of aerosols of dispersed surface active phospholipids by ultrasonic and jet nebulization. J Aerosol Sci 1983; 14: 683-94.
132. Edmondson C, Davies JC. Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications. Ther Adv Chronic Dis 2016; 7: 170-83.
133. Falco FG, Smith HM, Arcieri GM. Nephrotoxicity of aminoglycosides and gentamicin. J Infect Dis 1969; 119: 406-9.
134. Jackson GG, Arcieri G. Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States. J Infect Dis 1971; 124 (Suppl): S130-7.
135. Hirth RS, Nephrotoxicity of amikacin (BB-K8), an aminoglycoside antibiotic. Vet Pathol 1975; 12: 68-9.
136. Marier J-F, Lavigne J, Ducharme MP. Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection. Antimicrob Agents Chemother 2002; 46: 3776-81.
137. Marier J-F, Brazier JL, Lavigne J, Ducharme MP. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 2003; 52: 247-52.
138. Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008; 61: 859-68.
139. Mugabe C, Azghani AO, Omri A. Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2005; 55: 269-71.
140. Rukholm G, Mugabe C, Azghani AO, Omri A. Anibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Int J Antimicrob Agents 2006; 27: 247-52.
141. Elhissi A, Brar J, Najlah M, Roberts S, Faheem A, Taylor KMG. An ethanol-based proliposome technology for enhanced delivery and improved “respirability” of antiasthma aerosols generated using a micropump vibrating-mesh nebulizer. J Pharm Technol Res Manag 2013; 1: 171-80.
142. Waters V, Ratjen F. Inhaled liposomal amikacin. Expert Rev Respir Med 2014; 8: 401-9.